These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9698739)

  • 1. [Peripheral neuropathy investigation in the early stage of bone marrow transplantation].
    Zétola VH; Scola RH; Pasquini R; Werneck LC
    Arq Neuropsiquiatr; 1998 Jun; 56(2):267-73. PubMed ID: 9698739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
    Styler MJ; Crilley P; Biggs J; Moul J; Copelan E; Topolsky D; Avalos B; Penza S; Sabol P; Downs K; Szer J; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Jul; 18(1):171-6. PubMed ID: 8832011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
    Erer B; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Galimberti M; Giardini C; Gaziev D; Maiello A
    Bone Marrow Transplant; 1996 Jul; 18(1):157-62. PubMed ID: 8832009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
    Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
    van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic beta-cell function before and after bone marrow transplantation for thalassemia.
    Galimberti M; De Sanctis V; Lucarelli G; Polchi P; Angelucci E; Baronciani D; Giardini C; Erer B; Gaziev J; Balducci R
    Bone Marrow Transplant; 1993; 12 Suppl 1():102-3. PubMed ID: 8374544
    [No Abstract]   [Full Text] [Related]  

  • 7. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Subclinical lesions of peripheral nervous system in multiple sclerosis patients].
    Pogorzelski R; Baniukiewicz E; Drozdowski W
    Neurol Neurochir Pol; 2004; 38(4):257-64. PubMed ID: 15383952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The INFIR Cohort Study: assessment of sensory and motor neuropathy in leprosy at baseline.
    Van Brakel WH; Nicholls PG; Das L; Barkataki P; Maddali P; Lockwood DN; Wilder-Smith E
    Lepr Rev; 2005 Dec; 76(4):277-95. PubMed ID: 16411508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children.
    Shaw PJ; Hugh-Jones K; Hobbs JR; Downie CJ; Barnes R
    Bone Marrow Transplant; 1986 Dec; 1(2):193-200. PubMed ID: 3332132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Autologous bone marrow transplantation in children with malignant diseases. Bone marrow harvest and procedure-related toxicity].
    Schrøder H; Clausen N; Thorling K; Hokland P
    Ugeskr Laeger; 1993 May; 155(20):1536-9. PubMed ID: 8316985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
    Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
    Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between chronic exposure to arsenic and slow nerve conduction velocity among adolescents in Taiwan.
    Tseng HP; Wang YH; Wu MM; The HW; Chiou HY; Chen CJ
    J Health Popul Nutr; 2006 Jun; 24(2):182-9. PubMed ID: 17195559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
    Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distal sensory nerves of the lower extremity in peripheral neuropathy: comparison of medial dorsal cutaneous and sural nerve abnormalities.
    Izzo KL; Sobel E; Berney S; Demopoulos JT
    Arch Phys Med Rehabil; 1985 Jan; 66(1):7-10. PubMed ID: 2981521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
    Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral and nutritional status in allogeneic marrow recipients treated with T-cell depletion or cyclosporine combined with methotrexate to prevent graft-versus-host disease.
    Mattsson T; Heimdahl A; Dahllöf G; Lönnquist B; Ringdén O
    Oral Surg Oral Med Oral Pathol; 1992 Jul; 74(1):34-40. PubMed ID: 1508507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
    Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
    Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy.
    Thomas AE; Patterson J; Prentice HG; Brenner MK; Ganczakowski M; Hancock JF; Pattinson JK; Blacklock HA; Hopewell JP
    Bone Marrow Transplant; 1987 Apr; 1(4):347-55. PubMed ID: 3139113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.